A Phase 2 interventional study of VX-661 and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 39th largest by enrollment, is one of 2 that started in 2014, is one of 8 in phase 2, and was the 3rd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 2 started in 2014.
This study's enrollment of 40 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 83rd largest by enrollment of the 116 interventional ones that give a count, is one of 4 that started in 2014, is one of 21 in phase 2, and was the 34th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The objective of this study was to evaluate the safety and efficacy of VX-661in combination with ivacaftor in participants with cystic fibrosis (CF) who are homozygous for F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.
Drug: VX-661 · Drug: Ivacaftor
Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.
Drug: Placebo matched to VX-661 · Drug: Placebo matched to Ivacaftor
Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.
Drug: VX-661 · Drug: Ivacaftor
Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.
Drug: Placebo matched to VX-661 · Drug: Placebo matched to Ivacaftor
Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.
Drug: VX-661 · Drug: Ivacaftor
PC Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of PC Phase.
Time frame: Baseline (PC Phase) up to 112 days
OLE Phase: Number of Participants With Treatment-Emergent AEs and SAEs
AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of the OLE Phase.
Time frame: Baseline (OLE Phase) up to 364 days
PC Phase: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.
Time frame: Baseline (PC Phase), Through Week 12
OLE Phase: Absolute Change From Baseline in Percent Predicted FEV1 Through Week 40
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.
Time frame: Baseline (OLE Phase), Through Week 40
PC Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 12
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.
Time frame: Baseline (PC Phase), Through Week 12
OLE Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 40
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.
Time frame: Baseline (OLE Phase), Through Week 40
PC Phase: Absolute Change From Baseline in Sweat Chloride Through Week 12
Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of PC Phase.
Time frame: Baseline (PC Phase), Through Week 12
OLE Phase: Absolute Change From Baseline in Sweat Chloride Through Week 40
Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of the OLE Phase.
Time frame: Baseline (OLE Phase), Through Week 40
PC Phase: Absolute Change From Baseline in Body Weight at Week 12
Baseline was defined as Day 1 of PC Phase.
Time frame: Baseline (PC Phase), Week 12
OLE Phase: Absolute Change From Baseline in Body Weight at Week 40
Baseline was defined as Day 1 of the OLE Phase.
Time frame: Baseline (OLE Phase), Week 40
PC Phase: Absolute Change From Baseline Body Mass Index (BMI) at Week 12
BMI was calculated using following formula: BMI = Weight in kg/height in square meter (m\^2). Baseline was defined as Day 1 of PC Phase.
Time frame: Baseline (PC Phase), Week 12
OLE Phase: Absolute Change From Baseline BMI at Week 40
BMI was calculated using following formula: BMI = Weight in kg/height in m\^2. Baseline was defined as Day 1 of the OLE Phase.
Time frame: Baseline (OLE Phase), Week 40
PC Phase: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of PC Phase.
Time frame: Baseline (PC Phase), Through Week 12
OLE Phase: Absolute Change From Baseline in CFQ-R Respiratory Domain Score Through Week 40
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of the OLE Phase.
Time frame: Baseline (OLE Phase), Through Week 40
PC Phase: Maximum Plasma Concentration (Cmax) of VX-661 and IVA
Time frame: Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85
PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661
Pharmacokinetic (PK) sampling was performed up to 12 hours post-dose on Day 85. For Arm VX-661 50 mg q12h + IVA 150 mg q12h (VX-661 q12h regimen), area under the concentration versus time curve from time 0 to 12 hours (AUC0-12h) was multiplied by 2 to obtain AUC0-24h.
Time frame: Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85
PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 12 Hours (AUC0-12h) of IVA
Time frame: Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85
PC Phase: Time to Reach Cmax (Tmax) of VX-661 and IVA
Time frame: Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85
| Milestone | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h | OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|---|---|---|---|
| Started | 6 | 5 | 15 | 14 | 0 |
| Treated | 6 | 5 | 15 | 13 | 0 |
| Completed | 6 | 5 | 15 | 13 | 0 |
| Not completed | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Randomized, but not treated | 0 | 0 | 0 | 1 | 0 |
| Milestone | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h | OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 27 |
| Completed | 0 | 0 | 0 | 0 | 24 |
| Not completed | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 |
AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of PC Phase.
| Participants | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h |
|---|---|---|---|---|
| Participants with AEs | 6 | 5 | 15 | 13 |
| Participants with SAEs | 1 | 2 | 4 | 5 |
AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of the OLE Phase.
| Participants | OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|
| Participants with AEs | 25 |
| Participants with SAEs | 6 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.
| Percent predicted of FEV1 | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h |
|---|---|---|---|---|
| PC Phase: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12 | 0.9 (-3.1 to 5.0) | -0.1 (-4.4 to 4.3) | 3.0 (0.4 to 5.5) | 1.9 (-0.9 to 4.6) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.
| Percent predicted of FEV1 | OLE Phase:VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|
| OLE Phase: Absolute Change From Baseline in Percent Predicted FEV1 Through Week 40 | 2.7 (0.4 to 4.9) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.
| Percent change | PC Phase: VX-661 50 mg + IVA 150 mg | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h |
|---|---|---|---|---|
| PC Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 12 | 2.6 (-6.0 to 11.1) | 1.0 (-8.2 to 10.3) | 6.0 (0.6 to 11.3) | 4.2 (-1.5 to 10.0) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.
| Percent change | OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|
| OLE Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 40 | 6.1 (1.7 to 10.5) |
Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of PC Phase.
| Millimole per liter (mmol/L) | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h |
|---|---|---|---|---|
| PC Phase: Absolute Change From Baseline in Sweat Chloride Through Week 12 | -10.6 (-16.6 to -4.6) | 2.9 (-3.0 to 8.9) | -4.7 (-8.4 to -0.9) | 0.8 (-3.1 to 4.7) |
Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of the OLE Phase.
| mmol/L | OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|
| OLE Phase: Absolute Change From Baseline in Sweat Chloride Through Week 40 | -6.6 (-9.7 to -3.5) |
Baseline was defined as Day 1 of PC Phase.
| kilogram (kg) | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h |
|---|---|---|---|---|
| PC Phase: Absolute Change From Baseline in Body Weight at Week 12 | 1.0 (-0.4 to 2.3) | 1.6 (0.1 to 3.0) | 0.5 (-0.3 to 1.4) | 0.3 (-0.6 to 1.3) |
Baseline was defined as Day 1 of the OLE Phase.
| kg | OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|
| OLE Phase: Absolute Change From Baseline in Body Weight at Week 40 | 1.0 (-0.2 to 2.2) |
BMI was calculated using following formula: BMI = Weight in kg/height in square meter (m\^2). Baseline was defined as Day 1 of PC Phase.
| Kilogram per square meter (kg/m^2) | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h |
|---|---|---|---|---|
| PC Phase: Absolute Change From Baseline Body Mass Index (BMI) at Week 12 | 0.38 (-0.08 to 0.84) | 0.54 (0.03 to 1.04) | 0.18 (-0.11 to 0.47) | 0.11 (-0.21 to 0.42) |
BMI was calculated using following formula: BMI = Weight in kg/height in m\^2. Baseline was defined as Day 1 of the OLE Phase.
| kg/m^2 | OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|
| OLE Phase: Absolute Change From Baseline BMI at Week 40 | 0.33 (-0.09 to 0.74) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of PC Phase.
| units on a scale | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h |
|---|---|---|---|---|
| PC Phase: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12 | 5.6 (-3.9 to 15.1) | -4.6 (-14.9 to 5.7) | 1.0 (-5.1 to 7.0) | 0.4 (-6.2 to 7.1) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of the OLE Phase.
| units on a scale | OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|
| OLE Phase: Absolute Change From Baseline in CFQ-R Respiratory Domain Score Through Week 40 | -0.6 (-5.8 to 4.5) |
| Nanogram per milliliter (ng/mL) | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|---|
| VX-661 | 4890 ± 3150 | 6460 ± 1240 |
| IVA | 1490 ± 1150 | 1210 ± 585 |
Pharmacokinetic (PK) sampling was performed up to 12 hours post-dose on Day 85. For Arm VX-661 50 mg q12h + IVA 150 mg q12h (VX-661 q12h regimen), area under the concentration versus time curve from time 0 to 12 hours (AUC0-12h) was multiplied by 2 to obtain AUC0-24h.
| Hour*nanogram per milliliter (hr*ng/mL) | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|---|
| PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 | 84900 ± 55900 | 75500 ± 20300 |
| hr*ng/mL | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|---|
| PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 12 Hours (AUC0-12h) of IVA | 14700 ± 11600 | 10100 ± 4890 |
| hour | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|---|
| VX-661 | 2.48 (1.75 to 4.08) | 3.23 (1.92 to 6.03) |
| IVA | 3.59 (1.98 to 6.00) | 4.00 (2.98 to 6.03) |
Collected over Baseline (Day 1 of PC Phase) up to 112 days (Placebo control phase); Baseline (Day 1 of OLE Phase) up to 364 days (OLE phase). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| PC Phase: VX 661 Placebo q12h + IVA Placebo q12h | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | 0/15 (0%) | 4/15 (26.7%) | 15/15 (100%) |
| PC Phase: VX -661 Placebo qd + IVA Placebo q12h | 0/13 (0%) | 5/13 (38.5%) | 13/13 (100%) |
| OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h | 0/27 (0%) | 6/27 (22.2%) | 25/27 (92.6%) |
| Event | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX 661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h | OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/6 | 2/5 | 4/15 | 4/13 | 5/27 |
| Chronic sinusitisInfections and infestations | 1/6 | 0/5 | 0/15 | 0/13 | 0/27 |
| PneumoniaInfections and infestations | 0/6 | 0/5 | 0/15 | 1/13 | 0/27 |
| Intestinal obstructionGastrointestinal disorders | 0/6 | 0/5 | 0/15 | 1/13 | 0/27 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/6 | 0/5 | 0/15 | 1/13 | 0/27 |
| Cystic fibrosis related diabetesCongenital, familial and genetic disorders | 0/6 | 0/5 | 0/15 | 0/13 | 1/27 |
| DehydrationMetabolism and nutrition disorders | 0/6 | 0/5 | 0/15 | 0/13 | 1/27 |
| NephrolithiasisRenal and urinary disorders | 0/6 | 0/5 | 0/15 | 0/13 | 1/27 |
| Event | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX 661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h | OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h |
|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 1/6 | 3/5 | 5/15 | 4/13 | 13/27 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/6 | 2/5 | 4/15 | 5/13 | 10/27 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6 | 2/5 | 2/15 | 1/13 | 3/27 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 0/6 | 2/5 | 1/15 | 2/13 | 4/27 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/6 | 0/5 | 3/15 | 3/13 | 3/27 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/6 | 0/5 | 1/15 | 3/13 | 2/27 |
| Respiration abnormalRespiratory, thoracic and mediastinal disorders | 1/6 | 1/5 | 2/15 | 0/13 | 3/27 |
| Sputum discolouredRespiratory, thoracic and mediastinal disorders | 0/6 | 1/5 | 1/15 | 0/13 | 0/27 |
| RalesRespiratory, thoracic and mediastinal disorders | 0/6 | 1/5 | 0/15 | 1/13 | 0/27 |
| Pulmonary function test decreasedInvestigations | 1/6 | 1/5 | 2/15 | 1/13 | 0/27 |
Full Analysis Set (FAS) was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.
| Age, Continuous(years) | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h | Total |
|---|---|---|---|---|---|
| Mean | 33.0 ± 10.6 | 24.2 ± 2.2 | 27.3 ± 5.2 | 30.3 ± 10.8 | 28.8 ± 8.3 |
| Sex: Female, Male(Participants) | PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h | PC Phase: VX-661 Placebo q12h + IVA Placebo q12h | PC Phase: VX-661 100 mg qd + IVA 150 mg q12h | PC Phase: VX -661 Placebo qd + IVA Placebo q12h | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 7 | 3 | 14 |
| Male | 4 | 3 | 8 | 10 | 25 |
The record gives a start of Mar 2014, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 1 year 10 months after primary completion. A results delay was requested in Jun 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezacaftor
Vertex Pharmaceuticals Incorporated →